Grant: New Investigator Award - PA: HIV/AIDS Biomedical/Clinical Research
McGill University
$60,000.00
The potential of APOBEC3G in the development of a novel anti-HIV-1 therapeutic.
FY 2008-09
Summary
APOBEC3G is a host factor that is able to inhibit HIV-1 replication. A HIV-1 protein, so-called Vif, can protect the virus from the attack of APOBEC3G by binding to APOBEC3G and subsequently destroying it. Understanding the mechanism of how Vif protects HIV-1 from the inhibtion by APOBEC3G may lead us to develop a novel therapeutic strategy for HIV-1 infection. The objective of this work is to explore the mechanism by which Vif abolishes anti-HIV activity of APOBEC3G.
Department
Program
New Investigator Award - PA: HIV/AIDS Biomedical/Clinical Research
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
176402
Name
Cen Shan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
New Investigators C
Projecttitle
The potential of APOBEC3G in the development of a novel anti-HIV-1 therapeutic.
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
New Investigator Award - PA: HIV/AIDS Biomedical/Clinical Research
Keyworddelim
Aids; Apobec Superfamily; Apobec3g; Assembly; Deaminase; Encapsidation
Abstract
APOBEC3G is a host factor that is able to inhibit HIV-1 replication. A HIV-1 protein, so-called Vif, can protect the virus from the attack of APOBEC3G by binding to APOBEC3G and subsequently destroying it. Understanding the mechanism of how Vif protects HIV-1 from the inhibtion by APOBEC3G may lead us to develop a novel therapeutic strategy for HIV-1 infection. The objective of this work is to explore the mechanism by which Vif abolishes anti-HIV activity of APOBEC3G.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cen, Shan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $60,000~ $0~